Open Access Development of a simple LC-MS/MS method for determination of rebamipide in human plasma and its application to a bioequivalence study

 Download
(PDF 2,997.7kb)
 
Download Article:

Abstract:

The purpose of this study was to design a simple and rapid liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for a rebamipide bioequivalence study in healthy Chinese male volunteers. In this method, sample pretreatment involved simple protein precipitation with venlafaxine as the internal standard. Analysis was achieved on a ZORBAX SB-C18 column with a concentration range of 6∼1200 ng/mL. Rebamipide tablets from Yuanlijian (test, Hangzhou, China) and from Otsuka (reference, Hangzhou, China) were evaluated following a single 300 mg oral dose to 20 healthy volunteers. Bioequivalence was determined by calculating 90 % confidence intervals (90 % CI) for the ratio of C max, AUC 0–t and AUC 0–∞ values for the test and reference products, using logarithmic transformed data. The 90 % confidence intervals for the ratio of C max (83.7∼118.4 %), AUC 0–t (91.1∼113.4 %) and AUC 0–∞ (90.6∼113.2 %) values for the test and reference products were within the interval (80.0∼125.0 % for AUC, and 70∼143 % for C max), proposed by State of Food and Drug Administration [SFDA, 2005. China]. It was concluded that the two rebamipide tablets were bioequivalent in their rate and extent of absorption and the method met the principle of quick and easy clinical analysis.

Document Type: Research Article

DOI: http://dx.doi.org/10.1691/ph.2012.2018

Publication date: November 1, 2012

More about this publication?
  • Pharmazie is one of the world's leading pharmaceutical journals. As a peer-reviewed scientific journal, DiePharmazie is regularly indexed in Current Contents/Life Sciences, Excerpta Medica, Analytical Abstracts, International Pharmaceutical Abstracts, Beilstein Current Facts in Chemistry, Chemical Engineering and Biotechnology Abstracts (CEABA) and Science Citation Index.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • ingentaconnect is not responsible for the content or availability of external websites
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more